• Burmese
Tuesday, May 20, 2025
No Result
View All Result
NEWSLETTER
The Irrawaddy
22 °c
Ashburn
  • Home
  • News
    • Burma
    • Politics
    • World
    • Asia
    • Myanmar’s Crisis & the World
    • Ethnic Issues
    • War Against the Junta
    • Junta Cronies
    • Conflicts In Numbers
    • Junta Watch
    • Fact Check
    • Investigation
    • Myanmar-China Watch
    • Obituaries
  • Politics
  • Business
  • Opinion
    • Commentary
    • Guest Column
    • Analysis
    • Editorial
    • Stories That Shaped Us
    • Letters
  • Junta Watch
  • Ethnic Issues
  • War Against the Junta
  • In Person
    • Interview
    • Profile
  • Books
  • Donation
  • Home
  • News
    • Burma
    • Politics
    • World
    • Asia
    • Myanmar’s Crisis & the World
    • Ethnic Issues
    • War Against the Junta
    • Junta Cronies
    • Conflicts In Numbers
    • Junta Watch
    • Fact Check
    • Investigation
    • Myanmar-China Watch
    • Obituaries
  • Politics
  • Business
  • Opinion
    • Commentary
    • Guest Column
    • Analysis
    • Editorial
    • Stories That Shaped Us
    • Letters
  • Junta Watch
  • Ethnic Issues
  • War Against the Junta
  • In Person
    • Interview
    • Profile
  • Books
  • Donation
No Result
View All Result
The Irrawaddy
No Result
View All Result
Home News Asia

Japan Approves US-Made Drug Remdesivir to Treat COVID-19

Reuters by Reuters
May 8, 2020
in Asia
Reading Time: 2 mins read
0 0
A A
A lab technician loads vials of the COVID-19 treatment drug remdesivir at a Gilead Sciences facility in La Verne, California, on March 11, 2020. / REUTERS

A lab technician loads vials of the COVID-19 treatment drug remdesivir at a Gilead Sciences facility in La Verne, California, on March 11, 2020. / REUTERS

3.5k
VIEWS
Share on FacebookShare on Twitter

TOKYO—Japan on Thursday approved Gilead Sciences Inc.’s remdesivir as a treatment for COVID-19, making it the country’s first officially authorized drug to tackle the coronavirus disease.

Japan reached the decision just three days after the US drugmaker filed for fast-track approval for the treatment.

“There has so far been no coronavirus medicine available here so it is a significant step for us to approve this drug,” a Japanese health ministry official said at a press briefing. Remdesivir will be given to patients with severe COVID-19 symptoms, he added.

RelatedPosts

Myanmar’s NUG Names Controversial US Businessman as Envoy to Washington

Myanmar’s NUG Names Controversial US Businessman as Envoy to Washington

May 5, 2025
3.8k
From Resistance to Survival: Myanmar’s Free Press Battles US Aid Cuts

From Resistance to Survival: Myanmar’s Free Press Battles US Aid Cuts

April 28, 2025
1.2k
From Smog to Arsenic: Myanmar’s Toxic Trail Reaches Thailand

From Smog to Arsenic: Myanmar’s Toxic Trail Reaches Thailand

April 25, 2025
1.6k

With no other approved treatments for COVID-19, interest in the drug is growing around the world. Administered by intravenous infusion, it was granted authorization last week by the US Food and Drug Administration for emergency use for the disease caused by the novel coronavirus.

Gilead says the drug has improved outcomes for people suffering from the respiratory disease and has provided data suggesting it works better when given in the early stages of infection.

Japan, with just over 16,000 infections and under 800 deaths, has recorded fewer cases than other major industrialized nations.

However, a steady rise in cases has put pressure on medical facilities in some parts of the country, and a drug that helps patients recover more quickly could help in freeing up hospital beds.

A trial performed by the US Institutes of Health (NIH) showed the drug cut hospital stays by 31 percent compared with a placebo treatment, although it did not significantly improve survival.

On Monday, Japanese Prime Minister Shinzo Abe extended a monthlong state of emergency until the end of May in an attempt to slow the spread of the coronavirus.

Japan as yet does not know when it will get its first doses of remdesivir or how much, the ministry official said.

Gilead on Tuesday said it was in discussion with several companies, including generic drugmakers in India and Pakistan to produce remdesivir in large quantities.

Remdesivir, which previously failed as a treatment for Ebola, is designed to disable the ability by which some viruses make copies of themselves inside infected cells.

You may also like these stories:

Japan Mulls 1-Month Extension to State of Emergency Over Coronavirus

Your Thoughts …
Tags: COVID-19HealthJapanMedicineUS
Reuters

Reuters

...

Similar Picks:

China’s Export Ban is Causing Shortages of Medicine, Fuel And Food in Myanmar
Business

China’s Export Ban is Causing Shortages of Medicine, Fuel And Food in Myanmar

by The Irrawaddy
October 28, 2024
10k

Beijing’s crackdown on border trade with Myanmar is aggravating the post-coup economic crisis and the construction sector could see a...

Read moreDetails
Myanmar’s Youth Flee—and They Aren’t Looking Back
Commentary

Myanmar’s Youth Flee—and They Aren’t Looking Back

by Aung Zaw
February 23, 2024
8.3k

In Thailand and farther afield, they join the wealthy and the educated who have already put down roots and invested...

Read moreDetails
Japan’s ‘Special Relationship’ With Myanmar Has Abetted Decades of Military Rule
From the Archive

Japan’s ‘Special Relationship’ With Myanmar Has Abetted Decades of Military Rule

by Bertil Lintner
May 17, 2024
16.4k

In light of EAO and NUG leaders’ recent talks in Tokyo, The Irrawaddy revisits a column from 2022 exploring Japan’s...

Read moreDetails
Elon Musk Calls for Closure of Radio Free Europe, Voice of America
World

Elon Musk Calls for Closure of Radio Free Europe, Voice of America

by Naung Naung
February 10, 2025
7.1k

The billionaire’s call to shut down the US-funded media organizations, which reach hundreds of millions of people globally, follows his...

Read moreDetails
US Red-Faced as Contractor Lists Myanmar Resistance Groups in Terrorism Index
Myanmar’s Crisis & the World

US Red-Faced as Contractor Lists Myanmar Resistance Groups in Terrorism Index

by The Irrawaddy
December 12, 2023
5.5k

State Dept. contractor Development Services Group (DSG)'s inclusion of ethnic armies and PDFs in an annex to a US global...

Read moreDetails
Rare Earth Mining Taking Heavy Toll in Myanmar’s Kachin, Groups Say
Burma

Rare Earth Mining Taking Heavy Toll in Myanmar’s Kachin, Groups Say

by Hein Htoo Zan
May 27, 2024
5.3k

Amid heavy global demand for rare earths, local activists’ concerns about the impacts on the environment and local communities are...

Read moreDetails
Load More
Next Post
Workers clean the docks at Tien Sa port in Da Nang, Vietnam on March 6, 2020. / REUTERS

Vietnam Sets Sights on Post-Pandemic Business Boost

US President Donald Trump (left) and Japanese Prime Minister Shinzo Abe / Kyodo

Abe, Trump Affirm Cooperation on COVID-19 Response, Drugs

No Result
View All Result

Recommended

Myanmar Junta Leader Scores Diplomatic Win With Xi Meeting in Moscow

Myanmar Junta Leader Scores Diplomatic Win With Xi Meeting in Moscow

5 days ago
1.2k
How Myanmar Junta Uses Air Force to Fight Its Corner

How Myanmar Junta Uses Air Force to Fight Its Corner

7 days ago
1.3k

Most Read

  • China’s Two-Faced Diplomacy in Myanmar

    China’s Two-Faced Diplomacy in Myanmar

    shares
    Share 0 Tweet 0
  • Workers at Adidas Factory in Myanmar Strike for Living Wage

    shares
    Share 0 Tweet 0
  • Myanmar Political Parties Fear Mass Boycott of Junta’s Election

    shares
    Share 0 Tweet 0
  • Shan Party Says It’s Ready to Take Part in Junta’s Election

    shares
    Share 0 Tweet 0
  • Technical Problems Ground Myanmar’s JF-17 Fighter Jets Bought From China

    shares
    Share 0 Tweet 0

Newsletter

Get The Irrawaddy’s latest news, analyses and opinion pieces on Myanmar in your inbox.

Subscribe here for daily updates.

Contents

  • News
  • Politics
  • War Against the Junta
  • Myanmar’s Crisis & the World
  • Conflicts In Numbers
  • Junta Crony
  • Ethnic Issues
  • Asia
  • World
  • Business
  • Economy
  • Election 2020
  • Elections in History
  • Cartoons
  • Features
  • Opinion
  • Editorial
  • Commentary
  • Guest Column
  • Analysis
  • Letters
  • In Person
  • Interview
  • Profile
  • Dateline
  • Specials
  • Myanmar Diary
  • Women & Gender
  • Places in History
  • On This Day
  • From the Archive
  • Myanmar & COVID-19
  • Intelligence
  • Myanmar-China Watch
  • Lifestyle
  • Travel
  • Food
  • Fashion & Design
  • Videos
  • Photos
  • Photo Essay
  • Donation

About The Irrawaddy

Founded in 1993 by a group of Myanmar journalists living in exile in Thailand, The Irrawaddy is a leading source of reliable news, information, and analysis on Burma/Myanmar and the Southeast Asian region. From its inception, The Irrawaddy has been an independent news media group, unaffiliated with any political party, organization or government. We believe that media must be free and independent and we strive to preserve press freedom.

  • Copyright
  • Code of Ethics
  • Privacy Policy
  • Team
  • About Us
  • Careers
  • Contact
  • Burmese

© 2023 Irrawaddy Publishing Group. All Rights Reserved

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Home
  • News
    • Burma
    • Politics
    • World
    • Asia
    • Myanmar’s Crisis & the World
    • Ethnic Issues
    • War Against the Junta
    • Junta Cronies
    • Conflicts In Numbers
    • Junta Watch
    • Fact Check
    • Investigation
    • Myanmar-China Watch
    • Obituaries
  • Politics
  • Opinion
    • Commentary
    • Guest Column
    • Analysis
    • Editorial
    • Stories That Shaped Us
    • Letters
  • Ethnic Issues
  • War Against the Junta
  • In Person
    • Interview
    • Profile
  • Business
    • Economy
    • Business Roundup
  • Books
  • Donation

© 2023 Irrawaddy Publishing Group. All Rights Reserved

This website uses cookies. By continuing to use this website you are giving consent to cookies being used. Visit our Privacy and Cookie Policy.